February 2015

New Product - Fycompa

Fycompa (perampanel (as hemisesquihydrate)) is a first in class selective, noncompetitive antagonist of the ionotropic α-amino-3-hydroxy-5-methyl-4-isoxazoleproprionic acid (AMPA) glutamate receptor on postsynaptic neurons. The precise mechanism by which perampanel exerts its antiepileptic effects in humans remains to be fully elucidated. Fycompa is indicated for the adjunctive treatment of partial onset seizures with or without secondarily generalised seizures in patients with epilepsy aged 12 years and older. Fycompa is available as 2 mg tablets in packs of 7’s and 4 mg, 6 mg, 8 mg, 10 mg and 12 mg tablets in packs of 28’s.

This list is a summary of only some of the changes that have occurred over the last month. Before prescribing, always refer to the full product information.

Copyright © MIMS Australia Pty Ltd. All rights reserved.

MIMS Australia
Level 2, 1 Chandos Street
St Leonards NSW 2065
Phone: 1800 800 629